Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Christopher J WalkerClara D Bloomfield

Abstract

Uniparental disomy (UPD) is a way cancer cells duplicate a mutated gene, causing loss of heterozygosity (LOH). Patients with cytogenetically normal acute myeloid leukemia (CN-AML) do not have microscopically detectable chromosome abnormalities, but can harbor UPDs. We examined the prognostic significance of UPDs and frequency of LOH in patients with CN-AML.Experimental Design: We examined the frequency and prognostic significance of UPDs in a set of 425 adult patients with de novo CN-AML who were previously sequenced for 81 genes typically mutated in cancer. Associations of UPDs with outcome were analyzed in the 315 patients with CN-AML younger than 60 years. We detected 127 UPDs in 109 patients. Most UPDs were large and typically encompassed all or most of the affected chromosome arm. The most common UPDs occurred on chromosome arms 13q (7.5% of patients), 6p (2.8%), and 11p (2.8%). Many UPDs significantly cooccurred with mutations in genes they encompassed, including 13q UPD with FLT3-internal tandem duplication (FLT3-ITD; P < 0.001), and 11p UPD with WT1 mutations (P = 0.02). Among patients younger than 60 years, UPD of 11p was associated with longer overall survival (OS) and 13q UPD with shorter disease-free survival (DFS) ...Continue Reading

References

Apr 16, 2004·The New England Journal of Medicine·Peter J M ValkRuud Delwel
May 29, 2008·Genes, Chromosomes & Cancer·Manu GuptaBryan D Young
Jun 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter PaschkaClara D Bloomfield
Jul 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria R BaerRichard A Larson
Aug 5, 2009·Proceedings of the National Academy of Sciences of the United States of America·Matthew J WalterTimothy J Ley
Sep 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ramon V TiuJaroslaw P Maciejewski
Nov 12, 2010·The New England Journal of Medicine·Timothy J LeyRichard K Wilson
Apr 27, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hideki Makishima, Jaroslaw P Maciejewski
Nov 16, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jun Ho YiDong Hwan Kim
Nov 19, 2011·Hematology/oncology Clinics of North America·David Grimwade, Krzysztof Mrózek
Nov 26, 2011·Leukemia·S WeissmannA Kohlmann
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Jan 24, 2016·Bioinformatics·Karl W KrollJames S Blachly
Jun 9, 2016·The New England Journal of Medicine·Elli PapaemmanuilPeter J Campbell
Feb 15, 2017·Nature Communications·Julius GudmundssonKari Stefansson
Jun 24, 2017·The New England Journal of Medicine·Richard M StoneHartmut Döhner
Feb 22, 2018·Oncotarget·Nicolas DuployezClaude Preudhomme

❮ Previous
Next ❯

Citations

Oct 19, 2020·Bone Marrow Transplantation·David C ShyrAlice Bertaina

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.